BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cairns EA, Baldridge WH, Kelly ME. The Endocannabinoid System as a Therapeutic Target in Glaucoma. Neural Plast 2016;2016:9364091. [PMID: 26881140 DOI: 10.1155/2016/9364091] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Spadoni G, Bedini A, Furiassi L, Mari M, Mor M, Scalvini L, Lodola A, Ghidini A, Lucini V, Dugnani S, Scaglione F, Piomelli D, Jung K, Supuran CT, Lucarini L, Durante M, Sgambellone S, Masini E, Rivara S. Identification of Bivalent Ligands with Melatonin Receptor Agonist and Fatty Acid Amide Hydrolase (FAAH) Inhibitory Activity That Exhibit Ocular Hypotensive Effect in the Rabbit. J Med Chem 2018;61:7902-16. [DOI: 10.1021/acs.jmedchem.8b00893] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
2 Aizpurua-olaizola O, Elezgarai I, Rico-barrio I, Zarandona I, Etxebarria N, Usobiaga A. Targeting the endocannabinoid system: future therapeutic strategies. Drug Discovery Today 2017;22:105-10. [DOI: 10.1016/j.drudis.2016.08.005] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 13.0] [Reference Citation Analysis]
3 Toguri JT, Caldwell M, Kelly ME. Turning Down the Thermostat: Modulating the Endocannabinoid System in Ocular Inflammation and Pain. Front Pharmacol 2016;7:304. [PMID: 27695415 DOI: 10.3389/fphar.2016.00304] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
4 Abyadeh M, Gupta V, Paulo JA, Gupta V, Chitranshi N, Godinez A, Saks D, Hasan M, Amirkhani A, McKay M, Salekdeh GH, Haynes PA, Graham SL, Mirzaei M. A Proteomic View of Cellular and Molecular Effects of Cannabis. Biomolecules 2021;11:1411. [PMID: 34680044 DOI: 10.3390/biom11101411] [Reference Citation Analysis]
5 Di Zazzo A, Yang W, Coassin M, Micera A, Antonini M, Piccinni F, De Piano M, Kohler I, Harms AC, Hankemeier T, Boinini S, Mashaghi A. Signaling lipids as diagnostic biomarkers for ocular surface cicatrizing conjunctivitis. J Mol Med (Berl) 2020;98:751-60. [PMID: 32313985 DOI: 10.1007/s00109-020-01907-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
6 Jordan E, Nguyen GN, Piechot A, Kayser O. Cannabinoids as New Drug Candidates for the Treatment of Glaucoma. Planta Med 2022. [PMID: 35299275 DOI: 10.1055/a-1665-3100] [Reference Citation Analysis]
7 Nuzzi R, Tridico F. Glaucoma: Biological Trabecular and Neuroretinal Pathology with Perspectives of Therapy Innovation and Preventive Diagnosis. Front Neurosci 2017;11:494. [PMID: 28928631 DOI: 10.3389/fnins.2017.00494] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
8 Cairns EA, Szczesniak AM, Straiker AJ, Kulkarni PM, Pertwee RG, Thakur GA, Baldridge WH, Kelly MEM. The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice. J Ocul Pharmacol Ther 2017;33:582-90. [PMID: 28719234 DOI: 10.1089/jop.2017.0037] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
9 Garai S, Kulkarni PM, Schaffer PC, Leo LM, Brandt AL, Zagzoog A, Black T, Lin X, Hurst DP, Janero DR, Abood ME, Zimmowitch A, Straiker A, Pertwee RG, Kelly M, Szczesniak AM, Denovan-Wright EM, Mackie K, Hohmann AG, Reggio PH, Laprairie RB, Thakur GA. Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators. J Med Chem 2020;63:542-68. [PMID: 31756109 DOI: 10.1021/acs.jmedchem.9b01142] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
10 Ehrenkranz J, Levine MA. Bones and Joints: The Effects of Cannabinoids on the Skeleton. J Clin Endocrinol Metab 2019;104:4683-94. [PMID: 31393556 DOI: 10.1210/jc.2019-00665] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
11 Passani A, Posarelli C, Sframeli AT, Perciballi L, Pellegrini M, Guidi G, Figus M. Cannabinoids in Glaucoma Patients: The Never-Ending Story. J Clin Med 2020;9:E3978. [PMID: 33302608 DOI: 10.3390/jcm9123978] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
12 Garai S, Leo LM, Szczesniak AM, Hurst DP, Schaffer PC, Zagzoog A, Black T, Deschamps JR, Miess E, Schulz S, Janero DR, Straiker A, Pertwee RG, Abood ME, Kelly MEM, Reggio PH, Laprairie RB, Thakur GA. Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. J Med Chem 2021;64:8104-26. [PMID: 33826336 DOI: 10.1021/acs.jmedchem.1c00040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Kokona D, Spyridakos D, Tzatzarakis M, Papadogkonaki S, Filidou E, Arvanitidis KI, Kolios G, Lamani M, Makriyannis A, Malamas MS, Thermos K. The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity. Neuropharmacology 2021;185:108450. [PMID: 33450278 DOI: 10.1016/j.neuropharm.2021.108450] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
14 Nuzzi R, Marolo P, Nuzzi A. What Is New in Glaucoma: From Treatment to Biological Perspectives. J Ophthalmol 2021;2021:5013529. [PMID: 33936807 DOI: 10.1155/2021/5013529] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Shimamoto-Mitsuyama C, Nakaya A, Esaki K, Balan S, Iwayama Y, Ohnishi T, Maekawa M, Toyota T, Dean B, Yoshikawa T. Lipid Pathology of the Corpus Callosum in Schizophrenia and the Potential Role of Abnormal Gene Regulatory Networks with Reduced Microglial Marker Expression. Cereb Cortex 2021;31:448-62. [PMID: 32924060 DOI: 10.1093/cercor/bhaa236] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Lax P, Kutsyr O, Esquiva G, Altavilla C, Maneu V, Cuenca N. Cannabinoid-mediated retinal rescue correlates with improved circadian parameters in retinal dystrophic rats. Experimental Eye Research 2019;180:192-9. [DOI: 10.1016/j.exer.2018.12.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Tijani AO, Thakur D, Mishra D, Frempong D, Chukwunyere UI, Puri A. Delivering therapeutic cannabinoids via skin: Current state and future perspectives. J Control Release 2021;334:427-51. [PMID: 33964365 DOI: 10.1016/j.jconrel.2021.05.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Garai S, Schaffer PC, Laprairie RB, Janero DR, Pertwee RG, Straiker A, Thakur GA. Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure. Bioorg Med Chem 2021;50:116421. [PMID: 34634617 DOI: 10.1016/j.bmc.2021.116421] [Reference Citation Analysis]
19 Junaid MSA, Tijani AO, Puri A, Banga AK. In vitro percutaneous absorption studies of cannabidiol using human skin: Exploring the effect of drug concentration, chemical enhancers, and essential oils. Int J Pharm 2022;616:121540. [PMID: 35124116 DOI: 10.1016/j.ijpharm.2022.121540] [Reference Citation Analysis]
20 Caltana LR, Brusco A. Cannabinoids: A Group of Promising Neuroprotective Agents. In: Brahmachari G, editor. Neuroprotective Natural Products. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2017. pp. 321-39. [DOI: 10.1002/9783527803781.ch13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Zhou J, Kamali K, Lafreniere JD, Lehmann C. Real-Time Imaging of Immune Modulation by Cannabinoids Using Intravital Fluorescence Microscopy. Cannabis Cannabinoid Res 2021;6:221-32. [PMID: 34042507 DOI: 10.1089/can.2020.0179] [Reference Citation Analysis]
22 Panahi Y, Manayi A, Nikan M, Vazirian M. The arguments for and against cannabinoids application in glaucomatous retinopathy. Biomed Pharmacother 2017;86:620-7. [PMID: 28027538 DOI: 10.1016/j.biopha.2016.11.106] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
23 Bruni N, Della Pepa C, Oliaro-Bosso S, Pessione E, Gastaldi D, Dosio F. Cannabinoid Delivery Systems for Pain and Inflammation Treatment. Molecules 2018;23:E2478. [PMID: 30262735 DOI: 10.3390/molecules23102478] [Cited by in Crossref: 79] [Cited by in F6Publishing: 59] [Article Influence: 19.8] [Reference Citation Analysis]
24 Cvenkel B, Kolko M. Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment. J Ophthalmol 2020;2020:6138132. [PMID: 32774906 DOI: 10.1155/2020/6138132] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
25 Kwon YJ, Kim JH, Jung DH. Association Between Nonalcoholic Fatty Liver Disease and Intraocular Pressure in Korean Adults. J Glaucoma 2018;27:1099-104. [PMID: 30059409 DOI: 10.1097/IJG.0000000000001036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Hourani W, Alexander SPH. Cannabinoid ligands, receptors and enzymes: Pharmacological tools and therapeutic potential. Brain Neurosci Adv 2018;2:2398212818783908. [PMID: 32166144 DOI: 10.1177/2398212818783908] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
27 Mahmoudinoodezh H, Telukutla SR, Bhangu SK, Bachari A, Cavalieri F, Mantri N. The Transdermal Delivery of Therapeutic Cannabinoids. Pharmaceutics 2022;14:438. [DOI: 10.3390/pharmaceutics14020438] [Reference Citation Analysis]
28 Vallée A, Lecarpentier Y, Vallée JN. Cannabidiol and the Canonical WNT/β-Catenin Pathway in Glaucoma. Int J Mol Sci 2021;22:3798. [PMID: 33917605 DOI: 10.3390/ijms22073798] [Reference Citation Analysis]
29 Maccarone R, Rapino C, Zerti D, di Tommaso M, Battista N, Di Marco S, Bisti S, Maccarrone M. Modulation of Type-1 and Type-2 Cannabinoid Receptors by Saffron in a Rat Model of Retinal Neurodegeneration. PLoS One 2016;11:e0166827. [PMID: 27861558 DOI: 10.1371/journal.pone.0166827] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
30 Somvanshi RK, Zou S, Kadhim S, Padania S, Hsu E, Kumar U. Cannabinol modulates neuroprotection and intraocular pressure: A potential multi-target therapeutic intervention for glaucoma. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2022;1868:166325. [DOI: 10.1016/j.bbadis.2021.166325] [Reference Citation Analysis]
31 Madej K, Chmiołek A, Szlachta K, Piekoszewski W. HPLC-DAD Analysis of Hemp Oil Supplements for Determination of Four Cannabinoids: Cannabidiol, Cannabidiolic Acid, Cannabinol and Delta 9-Tetrahydrocannabinol. Separations 2021;8:227. [DOI: 10.3390/separations8120227] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Jiang S, Iliopoulos-Tsoutsouvas C, Tong F, Brust CA, Keenan CM, Raghav JG, Hua T, Wu S, Ho JH, Wu Y, Grim TW, Zvonok N, Thakur GA, Liu ZJ, Sharkey KA, Bohn LM, Nikas SP, Makriyannis A. Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists. J Med Chem 2021;64:3870-84. [PMID: 33761251 DOI: 10.1021/acs.jmedchem.0c02053] [Cited by in F6Publishing: 1] [Reference Citation Analysis]